Get the Stockscreener App
1.95
1.04%
0.02
Entera Bio Ltd stock is traded at $1.95, with a volume of 30,488.
It is up +1.04% in the last 24 hours and up +4.84% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.93
Open:
$1.92
24h Volume:
30,488
Relative Volume:
0.29
Market Cap:
$88.63M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-5.7353
EPS:
-0.34
Net Cash Flow:
$-6.72M
1W Performance:
+4.84%
1M Performance:
+4.84%
6M Performance:
-10.96%
1Y Performance:
+21.12%
1-Day Range:
$1.9153
$1.98
1-Week Range:
$1.9153
$2.35
52-Week Range:
$1.41
$2.79
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.95 | 87.72M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
What makes Entera Bio Ltd. stock price move sharplyFree Community Verified Stock Suggestions - Newser
Multi factor analysis applied to Entera Bio Ltd.Breakout Monitoring with Momentum Analysis - Newser
Sentiment analysis tools applied to Entera Bio Ltd.Stock Portfolio Risk and Return Analysis - Newser
Is Entera Bio Ltd. a growth stock or a value stockLow Risk Updates For Beginners - jammulinksnews.com
How Entera Bio Ltd. stock performs during market volatilityProfitable Trading Blueprint with Entry Zones - Newser
How to forecast Entera Bio Ltd. trends using time seriesBear Market Safe Zone Technical Analysis - Newser
What are analysts’ price targets for Entera Bio Ltd. in the next 12 monthsValue Investing Tracker To Watch Now - jammulinksnews.com
Entera Bio (ENTX) Projected to Post Earnings on Friday - Defense World
When is the best time to buy Entera Bio Ltd. stockHigh Return Trade Roadmap with Setup Filters - Newser
How volatile is Entera Bio Ltd. stock compared to the marketBest Dividend Tracker For Every Investor - jammulinksnews.com
Why Entera Bio Ltd. stock attracts strong analyst attentionBuy Signal Forecast With Short-Term Data - Newser
How strong is Entera Bio Ltd. company’s balance sheetReal Time Signals For Consistent Profits - jammulinksnews.com
Entera Bio Ltd. Stock (ENTX) Opinions on FDA Agreement for EB613 Endpoint - Quiver Quantitative
How did ENTX's revenue and expenses trend in Q4 2024? - AInvest
Is Entera Bio Ltd. stock reversal real or fakeEntry Zone Forecast for Momentum Trading - Newser
Entera Bio (NASDAQ:ENTX) Trading Up 10.8% – What’s Next? - Defense World
Entera Bio Receives FDA Agreement on BMD as Primary - GlobeNewswire
Entera Bio Ltd. Recovery Hinges on Volume BreakoutFast Entry High Potential Stock Alerts Triggered - metal.it
What is the dividend policy of Entera Bio Ltd. stockDiscover investment plans that deliver results - jammulinksnews.com
Entera Bio stock surges after FDA agrees on BMD endpoint for EB613 By Investing.com - Investing.com South Africa
Entera Bio stock surges after FDA agrees on BMD endpoint for EB613 - Investing.com Nigeria
FDA agrees to BMD endpoint for Entera’s oral osteoporosis drug By Investing.com - Investing.com South Africa
Entera Bio Advances EB613 with FDA Approval - TipRanks
FDA Agrees to BMD Endpoint for First Oral Osteoporosis Drug Phase 3 Trial | ENTX Stock News - Stock Titan
Is it the right time to buy Entera Bio Ltd. stockHigh-profit stock alerts - jammulinksnews.com
What is Entera Bio Ltd. company’s growth strategyDiscover stocks with explosive upside potential - jammulinksnews.com
How does Entera Bio Ltd. compare to its industry peersRapid-fire capital growth - jammulinksnews.com
Does Entera Bio Ltd. stock perform well during market downturnsStay ahead with daily market updates - jammulinksnews.com
When is Entera Bio Ltd. stock expected to show significant growthFree Stock Selection - jammulinksnews.com
Entera Bio Ltd. Stock Analysis and ForecastGame-changing capital returns - PrintWeekIndia
Is Entera Bio Ltd. stock a good hedge against inflationSuperior returns - jammulinksnews.com
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):